Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00286728
Other study ID # IIR 05-014
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2006
Est. completion date September 2010

Study information

Verified date April 2019
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project will help counselors in substance abuse treatment programs make effective referrals of dually diagnosed patients (those with a co-occurring psychiatric disorder) to self-help groups.


Description:

Background:

Dual diagnosis (psychiatric and substance use) patients' (DDPs) participation in 12-step mutual-help groups is linked to lower relapse and treatment utilization rates. However, under usual referral, many DDPs do not attend, or sustain attendance of, substance-focused groups (SFG). DDPs may benefit from dual-focused groups (DFGs).

Objectives:

(1) Implement and validate procedures to help counselors make effective referrals to DFGs. DDPs were assigned to a standard- or intensive-referral to DFG condition to determine the extent to which intensive referral, compared to standard referral, increased patients' mutual-help group participation. (2) Determine whether DDPs who received intensive referral had better substance use and psychiatric outcomes.

Methods:

DDPs entering VA outpatient mental health treatment received either standard (N=145) or intensive (N=142) referral. Standard referral consisted essentially of the counselor recommending DFG participation. The keys to intensive referral were a DFG orientation and the counselor facilitating direct contact between the patient and a DFG member, and following up on recommendations for mutual help. Patients were followed at six months (80%), one year (81%) and two years (80%) to determine whether intensive referral resulted in more DFG and SFG participation, and better substance use and psychiatric outcomes.

Status:

Completed.


Recruitment information / eligibility

Status Completed
Enrollment 287
Est. completion date September 2010
Est. primary completion date September 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Dually diagnosed veterans entering outpatient mental health treatment

Exclusion Criteria:

- Unable to correctly answer the Orientation and Registration questions of the Mini-Mental State Examination

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Intensive referral to dual-focused self-help
4 group sessions to introduce patients to dual focused groups

Locations

Country Name City State
United States VA Palo Alto Health Care System, Palo Alto, CA Palo Alto California

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

References & Publications (4)

Makin-Byrd K, Cronkite RC, Timko C. The influence of abuse victimization on attendance and involvement in mutual-help groups among dually diagnosed male veterans. J Subst Abuse Treat. 2011 Jul;41(1):78-87. doi: 10.1016/j.jsat.2011.02.001. Epub 2011 Mar 10 — View Citation

Timko C, Cronkite RC, McKellar J, Zemore S, Moos RH. Dually diagnosed patients' benefits of mutual-help groups and the role of social anxiety. J Subst Abuse Treat. 2013 Feb;44(2):216-23. doi: 10.1016/j.jsat.2012.05.007. Epub 2012 Jul 3. — View Citation

Timko C, Sutkowi A, Moos R. Patients with dual diagnoses or substance use disorders only: 12-step group participation and 1-year outcomes. Subst Use Misuse. 2010 Mar;45(4):613-27. doi: 10.3109/10826080903452421. — View Citation

Timko C. Detoxification history and two-year outcomes of substance use disorder treatment and mutual-help group participation. Journal of drug issues. 2013 Jun 17; 20(10):1-18.

Outcome

Type Measure Description Time frame Safety issue
Primary Psychiatric Functioning at 6 Months Addiction Severity Index psychiatric composite ranges from 0 to 1, with 1 indicating more severe problems. 6 months
Secondary Mental Health Services Use and Costs at 6 Months, 1 Year, and 2 Years 6 months, 1 year, 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05054738 - CRP and S&A for Inpatient Veterans N/A
Completed NCT02233738 - Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services N/A
Completed NCT02192931 - A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users Phase 4
Completed NCT00970372 - Dual-Diagnosis and Compulsory Treatment N/A
Completed NCT02520271 - Ostrobothnia Depression Study (ODS). A Naturalistic Follow-up Study on Depression and Related Substance Use Disorders N/A
Completed NCT00498550 - Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual Phase 4
Not yet recruiting NCT06315660 - VR Based Therapy to Treat Anxiety in Dual Diagnosis N/A
Recruiting NCT06311838 - Building Social and Structural Connections for the Prevention of Opioid Use Disorder Among Youth Experiencing Homelessness N/A
Completed NCT00706901 - Impact of Group Motivational Interviewing and In-Home-Messaging-Devices for Dually Diagnosed Veterans N/A
Terminated NCT00169026 - Alcoholism and Schizophrenia: Effects of Clozapine Phase 4
Completed NCT01639872 - Clozapine for Cannabis Use in Schizophrenia Phase 4
Active, not recruiting NCT02404662 - Trial of Supportive Text Messages for Patients With Alcohol Use Disorder and a Co-morbid Depression N/A
Completed NCT00218582 - Effectiveness of Self-Help for Dually-Diagnosed Persons - 1 Phase 1/Phase 2
Recruiting NCT04105231 - Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use Phase 2
Completed NCT01964404 - Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment? Phase 1
Completed NCT00105768 - Effectiveness of Advisor-Teller Money Manager Phase 1/Phase 2
Completed NCT01514630 - Creatine as a Treatment Option for Depression in Methamphetamine Using Females Phase 4
Terminated NCT02189915 - Open-Label Creatine Study for Female Meth Users N/A
Completed NCT02082678 - Ondansetron for Bipolar Disorder and Alcohol Use Disorders Phase 4
Completed NCT01411085 - Risperidone and Desipramine in Alcohol Use and Schizophrenia Phase 2